Tagged with M

Spain After decades of investment, Catalonia has secured its healthcare and life sciences hub status, accounting for more than half of Spain’s pharma exports and with more clinical trials than any other region. The birthplace of many of the country’s pharma success stories, Catalonia boasts a strong scientific output by European…

Global Due to lowered global demand, for the first time, Pfizer/BioNTech and Moderna are expected to see sales revenues for their COVID-19 vaccines take a major fall in Q2, but sales are expected to bounce back with jabs targeting new variants. According to Airfinity’s recent forecast, revenue for Pfizer/BioNTech’s vaccine will…

Spain Its unorthodox name reflecting a somewhat unconventional approach, mAbxience has achieved some significant milestones in its short history, including becoming the only privately-owned company in the world with less than 500 people to have launched a monoclonal antibody biosimilar. “This is not usually a small company game, and mAbxience did…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Italy ENEA Tech and Biomedical is a foundation supervised by the Italian Ministry of Economic Development that aims to strengthen Italian R&D and the industrial transformation of the country’s biomedical sector. Its managing director, Marco Baccanti, outlines the organisation’s strategy to support and fund projects and analyses the current state of…

India Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework.   In April 2018, the India Ministry of Health and Family Welfare launched the National Patient Safety Implementation Framework 2018-2025 (NPSIF),…

Africa David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the push to establish vaccine manufacturing facilities on the continent.   Since the minimum number of 15 ratifications by African Union…

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

USA US generics giant Mallinckrodt, which declared bankruptcy in 2020 after a stream of litigation regarding its role in the opioid epidemic and underpaying Medicaid rebates for its drug Acthar, has announced a new strategic plan and CEO as it emerges from its “restructuring process.”   Controversy on Controversy The USA’s…

China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…